TherapeuticsMD Inc (NASDAQ:TXMD) – Research analysts at Jefferies Group lowered their FY2020 earnings estimates for shares of TherapeuticsMD in a report released on Tuesday. Jefferies Group analyst M. Andrews now anticipates that the company will post earnings of $0.29 per share for the year, down from their prior estimate of $0.34.
Several other equities analysts have also commented on the company. BidaskClub upgraded TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 25th. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research note on Thursday, November 30th. Cowen reiterated an “outperform” rating and issued a $16.00 target price (up previously from $13.00) on shares of TherapeuticsMD in a research note on Monday, November 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $31.00 target price on shares of TherapeuticsMD in a research note on Wednesday, November 29th. Finally, Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. TherapeuticsMD currently has an average rating of “Buy” and an average price target of $14.50.
Shares of TherapeuticsMD (NASDAQ TXMD) traded up $0.09 during trading on Wednesday, hitting $5.47. The stock had a trading volume of 1,426,000 shares, compared to its average volume of 1,796,648. The stock has a market capitalization of $1,190.00, a price-to-earnings ratio of -14.03 and a beta of 0.99. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.
In related news, Director Tommy G. Thompson bought 5,000 shares of the business’s stock in a transaction on Friday, December 8th. The shares were bought at an average price of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the purchase, the director now directly owns 3,555 shares of the company’s stock, valued at $22,076.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 23.92% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of TXMD. Schwab Charles Investment Management Inc. boosted its holdings in TherapeuticsMD by 10.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after acquiring an additional 67,855 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in TherapeuticsMD by 3.9% in the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after acquiring an additional 818 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in TherapeuticsMD by 10.8% in the second quarter. Alliancebernstein L.P. now owns 254,240 shares of the company’s stock worth $1,340,000 after acquiring an additional 24,700 shares in the last quarter. TIAA CREF Investment Management LLC boosted its holdings in TherapeuticsMD by 7.7% in the second quarter. TIAA CREF Investment Management LLC now owns 421,181 shares of the company’s stock worth $2,220,000 after acquiring an additional 30,183 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in TherapeuticsMD by 7.2% in the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after acquiring an additional 1,322 shares in the last quarter. Institutional investors own 72.65% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Jefferies Group Weighs in on TherapeuticsMD Inc’s FY2020 Earnings (TXMD)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/15/jefferies-group-weighs-in-on-therapeuticsmd-incs-fy2020-earnings-txmd.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.